Teva Pharmaceutical Industries Limited (TEV) - Net Assets

Latest as of March 2026: €8.23 Billion EUR ≈ $9.62 Billion USD

Based on the latest financial reports, Teva Pharmaceutical Industries Limited (TEV) has net assets worth €8.23 Billion EUR (≈ $9.62 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€40.04 Billion ≈ $46.81 Billion USD) and total liabilities (€31.81 Billion ≈ $37.19 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Teva Pharmaceutical Industries Limited (TEV) tangible net worth to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	€8.23 Billion
% of Total Assets	20.56%
Annual Growth Rate	-12.45%
5-Year Change	-29.62%
10-Year Change	-77.38%
Growth Volatility	23.28

Teva Pharmaceutical Industries Limited - Net Assets Trend (2015–2025)

This chart illustrates how Teva Pharmaceutical Industries Limited's net assets have evolved over time, based on quarterly financial data. See Teva Pharmaceutical Industries Limited (TEV) liquidity interval to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Teva Pharmaceutical Industries Limited (2015–2025)

The table below shows the annual net assets of Teva Pharmaceutical Industries Limited from 2015 to 2025. For live valuation and market cap data, see Teva Pharmaceutical Industries Limited market cap and net worth.

Year	Net Assets	Change
2025-12-31	€7.91 Billion ≈ $9.25 Billion	+38.36%
2024-12-31	€5.72 Billion ≈ $6.69 Billion	-29.61%
2023-12-31	€8.13 Billion ≈ $9.50 Billion	-6.50%
2022-12-31	€8.69 Billion ≈ $10.16 Billion	-22.71%
2021-12-31	€11.24 Billion ≈ $13.15 Billion	+1.65%
2020-12-31	€11.06 Billion ≈ $12.93 Billion	-26.57%
2019-12-31	€15.06 Billion ≈ $17.61 Billion	-4.63%
2018-12-31	€15.79 Billion ≈ $18.46 Billion	-15.74%
2017-12-31	€18.75 Billion ≈ $21.91 Billion	-46.43%
2016-12-31	€34.99 Billion ≈ $40.91 Billion	+16.93%
2015-12-31	€29.93 Billion ≈ $34.99 Billion	--

Equity Component Analysis

This analysis shows how different components contribute to Teva Pharmaceutical Industries Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 192.7% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Other Components	€21.67 Billion	273.98%
Total Equity	€7.91 Billion	100.00%

Teva Pharmaceutical Industries Limited Competitors by Market Cap

The table below lists competitors of Teva Pharmaceutical Industries Limited ranked by their market capitalization.

Company	Market Cap
People's Insurance of China Ltd SHG:601319	$34.59 Billion
Trip.com Group Ltd ADR NASDAQ:TCOM	$34.61 Billion
JSW Steel Limited NSE:JSWSTEEL	$34.65 Billion
Telefonaktiebolaget LM Ericsson B ADR NASDAQ:ERIC	$34.77 Billion
Intact Financial Corporation TO:IFC	$34.55 Billion
SSE PLC ADR LS-50 1 F:SCTA	$34.54 Billion
Powszechna Kasa Oszczednosci Bank Polski SA WAR:PKO	$34.53 Billion
HCL Technologies Limited NSE:HCLTECH	$34.50 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Teva Pharmaceutical Industries Limited's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 5,373,000,000 to 7,910,000,000, a change of 2,537,000,000 (47.2%).
Net income of 1,410,000,000 contributed positively to equity growth.
Other factors increased equity by 1,127,000,000.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	€1.41 Billion	+17.83%
Other Changes	€1.13 Billion	+14.25%
Total Change	€-	47.22%

Book Value vs Market Value Analysis

This analysis compares Teva Pharmaceutical Industries Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 4.42x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has increased from 1.78x to 4.42x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2017-12-31	€17.07	€30.40	x
2018-12-31	€13.50	€30.40	x
2019-12-31	€12.79	€30.40	x
2020-12-31	€9.14	€30.40	x
2021-12-31	€9.32	€30.40	x
2022-12-31	€7.11	€30.40	x
2023-12-31	€6.70	€30.40	x
2024-12-31	€4.74	€30.40	x
2025-12-31	€6.88	€30.40	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Teva Pharmaceutical Industries Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 17.83%
The company demonstrates strong efficiency in generating profits from shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 8.17%
• Asset Turnover: 0.42x
• Equity Multiplier: 5.15x
Recent ROE (17.83%) is above the historical average (-17.65%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2015	6.00%	8.08%	0.36x	2.05x	€-1.06 Billion
2016	0.99%	1.50%	0.24x	2.79x	€-3.00 Billion
2017	-93.70%	-72.66%	0.32x	4.07x	€-18.00 Billion
2018	-14.62%	-11.40%	0.31x	4.13x	€-3.62 Billion
2019	-7.15%	-5.92%	0.29x	4.11x	€-2.40 Billion
2020	-39.80%	-23.95%	0.33x	5.05x	€-4.99 Billion
2021	4.06%	2.63%	0.33x	4.64x	€-610.80 Million
2022	-29.80%	-15.77%	0.34x	5.57x	€-3.14 Billion
2023	-7.45%	-3.53%	0.36x	5.79x	€-1.31 Billion
2024	-30.50%	-9.91%	0.42x	7.32x	€-2.18 Billion
2025	17.83%	8.17%	0.42x	5.15x	€619.00 Million

Industry Comparison

This section compares Teva Pharmaceutical Industries Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $6,817,214,049
Average return on equity (ROE) among peers: -32.24%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Teva Pharmaceutical Industries Limited (TEV)	€8.23 Billion	6.00%	3.86x	$34.58 Billion
SHANG.FOS.PHARM.GR.H YC 1 (08HH)	$59.93 Billion	4.62%	0.96x	$1.19 Billion
PEPTONIC MEDICAL (28L)	$48.55 Million	-123.64%	0.45x	$4.14 Million
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ)	$7.85 Billion	28.40%	0.37x	$692.11 Million
WEST ISLAND BRANDS INC. (39N0)	$3.27 Million	-157.21%	0.88x	$1.34 Million
AYURCANN HOLDINGS CORP. (3ZQ0)	$4.89 Million	-63.10%	0.49x	$97.35K
CERENO SCIENTIFIC AB B (4A1)	$201.51 Million	-13.72%	0.07x	$157.72 Million
MAPLE LEAF GREEN WORLD (4HV0)	$-9.91 Million	0.00%	0.00x	$504.30K
LORDS CO. WORLDW. HOLD. (4XM)	$-815.79K	0.00%	0.00x	$134.78K
RED LIGHT HOLLAND CORP. (4YX)	$17.35 Million	-23.30%	0.22x	$13.93 Million
EQL PHARMA AB (7JK)	$123.63 Million	25.52%	0.92x	$72.84 Million

About Teva Pharmaceutical Industries Limited

F:TEV Germany Drug Manufacturers - Specialty & Generic

Market Cap

$41.38 Billion

€35.40 Billion EUR

Market Cap Rank

#782 Global

#169 in Germany

Share Price

€30.40

Change (1 day)

+16.03%

52-Week Range

€13.15 - €30.50

All Time High

€57.25